Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EPS (Weighted Average and Diluted) (2016 - 2025)

Cytokinetics (CYTK) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$2.54 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed N/A to -$2.54 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.57 through Dec 2025, changed N/A year-over-year, with the annual reading at -$6.54 for FY2025, 24.33% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$2.54 at Cytokinetics, roughly flat from -$2.55 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.23 in Q2 2022, with the low at -$2.55 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.3, with a median of -$1.35 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 99.95% in 2021, then tumbled 482.61% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.32 in 2021, then crashed by 362.5% to -$1.48 in 2022, then rose by 6.76% to -$1.38 in 2023, then grew by 1.45% to -$1.36 in 2024, then crashed by 86.76% to -$2.54 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$2.54, -$2.55, and -$1.12 for Q4 2025, Q3 2025, and Q2 2025 respectively.